Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEO-GEAR study of necitumumab in EGFR-amplified advanced esophageal or gastric cancer
jRCT2031240655Phase 2Recruiting
- Sponsor
- Nippon Kayaku Co., Ltd.
- Start
- Jun 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of necitumumab in esophageal cancer, gastric cancer (GC) and gastroesophageal junction adenocarcinoma (2 cohorts), sponsored by Nippon Kayaku Co., Ltd. Primary endpoint: Overall response rate. Started Jun 2025; status: recruiting.
02
Drugs
necitumumab
03
Conditions
esophageal cancergastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCT2031240655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240655.